1. Home
  2. CSTE vs ANL Comparison

CSTE vs ANL Comparison

Compare CSTE & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CSTE

Caesarstone Ltd.

HOLD

Current Price

$0.64

Market Cap

27.7M

Sector

Industrials

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$7.98

Market Cap

293.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTE
ANL
Founded
1987
2004
Country
Israel
Cayman Islands
Employees
N/A
123
Industry
Building Materials
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
293.4M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
CSTE
ANL
Price
$0.64
$7.98
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$16.00
AVG Volume (30 Days)
333.9K
215.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.43
N/A
Revenue Next Year
$2.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.88
52 Week High
$3.26
$12.09

Technical Indicators

Market Signals
Indicator
CSTE
ANL
Relative Strength Index (RSI) 18.09 47.12
Support Level N/A $7.21
Resistance Level $2.00 $9.98
Average True Range (ATR) 0.17 1.05
MACD -0.06 -0.31
Stochastic Oscillator 7.02 25.68

Price Performance

Historical Comparison
CSTE
ANL

About CSTE Caesarstone Ltd.

Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: